Copenhagen, 31 May 2010 - NeuroSearch A/S (NEUR) announced today that Chief
Executive Officer Flemming Pedersen has decided to resign from his position at
NeuroSearch to take up a new position in another company. The final date for
Flemming Pedersen's resignation has not yet been determined but will be no
later than 30 November 2010.

The Board of Directors of NeuroSearch will now initiate a process to find a new
CEO who together with the rest of the management team can pursue and further
develop the agreed strategy to sustain the continued growth of the company. To
ensure a smooth transition, Flemming Pedersen will continue to undertake the
daily corporate management until a successor is in place.

Flemming Pedersen has been employed at NeuroSearch for almost ten years and
hereof the last four years in his current position as CEO.

Thomas Hofman-Bang, Chairman of the Board in NeuroSearch, commented;

"The Board of Directors wishes to thank Flemming Pedersen for a valuable
contribution to NeuroSearch. Untill a new CEO has been found, the board will
work together with the existing executive management further towards
realisation of the company's strategic goals."


Thomas Hofman-Bang
Chairman of the Board


Contact persons:

Thomas Hofman-Bang, Chairman of the Board, telephone; +45 4348 3202

Flemming Pedersen, CEO, telephone; +45 4460 8214 or +45 2148 0118

Hanne Leth Hillman, Vice President, Director of IR & Corporate Communications,
telephone; +45 4460 8212 or +45 4017 5103


NeuroSearch - Company profile
NeuroSearch (NEUR) is a Scandinavian biopharmaceutical company listed on NASDAQ
OMX Copenhagen A/S. The company's core business covers the development of novel
drugs, based on a broad and well-established drug discovery platform focusing
on ion channels and central nervous system (CNS) disorders. A substantial share
of the activities is partner financed through strategic alliances with Eli
Lilly and Janssen and a license collaboration with Abbott. The drug pipeline
comprises eight clinical (Phase I-III) development programmes: Huntexil® for
Huntington's disease (Phase III), tesofensine for obesity (Phase III), ABT-894
for ADHD (Phase II) in partnership with Abbott, ACR343 for schizophrenia (Phase
II ready), ACR325 to treat dyskinesias in Parkinson's disease (Phase Ib),
ABT-560 for the treatment of cognitive dysfunctions (Phase I) in collaboration
with Abbott, NSD-788 for anxiety/depression (Phase I) and NSD-721 for social
anxiety disorder (Phase I). In addition, NeuroSearch has a broad portfolio of
preclinical drug candidates and holds equity interests in several biotech
companies.